Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 8/1/2000
Phase: II
Open-label, single-arm, multicenter study on the efficacy and safety of intermittent, intravenous administration if BM 21.0955 (2.0 mg every 3 months) during 12 months’ treatment of corticosteroid-induced osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 8/1/2000
Phase: II
Open-label, single-arm, multicenter, follow-up study on the efficacy and safety of intermittent, intravenous administration of BM 21.0955 (1.0 mg every 3 months) during 3 years’ treatment of patients with post-menopausal osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 7/1/2001
Phase: III
A two-center, randomized, comparative study using 2 mg intermittent iv ibandronate and 10 mg daily oral alendronate during 2 years in the treatment of post-menopausal osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 9/1/2001
Phase: II
Open, monocenter, pilot-study on the efficacy and safety of intermittent, intravenous administration of BM 21.0955 (2.0 mg every three months) during 2 years’ treatment in male patients with osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 10/1/2001
Phase: III
A multicenter, open label, randomized study on the efficacy and safety of oral ibandronate (BM 21.0955) 2.5 mg taken either 30 or 60 minutes before breakfast during 12 months treatment in patients with postmenopausal osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 3/1/2002
Phase: II
Multicenter, double-blind, placebo-controlled, randomized, dose-finding study on the efficacy and safety of ibandronate (BM 21.0955) during 2 years’ treatment in patients with postmenopausal osteoporosis using an intermittent (every 3 months) iv injection of 1 mg or 2 mg.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 4/1/2002
Phase: II
A single-center, randomized, parallel and cross-over, placebo-controlled study of the efficacy and safety of daily and intermittent ibandronate administration in the treatment of postmenopausal osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2002
Phase: III
Efficacy and safety of long-term, intermittent iv ibandronate treatment in women with postmenopausal osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2002
Phase: III
Double-blind, placebo-controlled, randomized, multicenter study on the efficacy and safety of ibandronate (BM 21.0955) during an extended two year parallel group study of patients enrolled in MF 4380 (3-year post-menopausal osteoporosis treatment study) using an intermittent i.v. injection regimen of 0.5 mg and 1 mg every 3 months.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2002
Phase: III
Double-blind, placebo-controlled, randomized, multicenter study of the efficacy and safety of ibandronate (BM 21.0955) during an extended two year partial crossover study of patients enrolled in MF 4380 (3-year post-menopausal osteoporosis treatment study) using an intermittent i.v. injection regimen of 0.5 mg and 1 mg every 3 months.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2002
Phase: III
Multicenter, double-blind, placebo-controlled, randomized study on the efficacy and safety of ibandronate over 3 years in patients with postmenopausal osteoporosis using a continuous oral and an intermittent oral dosing regimen.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 6/30/2005
Phase: IV
Randomized, Open-Label, Multi-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A 6-Month, 2-Sequence, and 2-Period Crossover Study
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 9/1/2005
Phase: III
DIVA study. Randomized, Double-Blind, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of 2 intravenous (iv) Ibandronate Dose Regimens (2 mg q 2 mo, 3 mg q 3 mo) With 2.5 mg Daily Oral Ibandronate in Postmenopausal Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 9/29/2005
Phase: III
Randomized, Double-Blind, Double-Dummy, Parallel Groups, Multi-Center Study to Compare the Efficacy and Safety of Monthly Oral Administration of 100 mg and 150 mg Ibandronate with 2.5 mg Daily Oral Ibandronate in Post-Menopausal Osteoporosis; Year 2 Analysis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 1/1/2006
Phase: IV
Randomized, Open-Label, Multi-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A 6-Month, 2-Sequence, and 2-Period Crossover Study
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Once Monthly Bonviva (Ibandronate) in Women with Post-Menopausal Osteoporosis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
ATOM Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Adherence to Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: III
A Study of Adherence to Bonviva (ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: III
A Study Comparing Monthly Bonviva (ibandronate) and Weekly Alendronate in Women with Post-Menopausal Osteoporosis
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2006
Phase: IV
Randomised, open-label, multi-centre, study designed to reflect routine clinical care in order to assess persistence on treatment in women with post-menopausal osteoporosis receiving once-monthly ibandronate with a patient support programme versus once-weekly alendronate.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
SUMMIT Study: A Study of Persistence to Bonviva (ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: III
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 9/1/2006
Phase: IV
A prospective, open-label, multi-center, two-part study to investigate patient satisfaction with monthly dosed ibandronate therapy in women with postmenopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 9/1/2006
Phase: IV
A prospective, open-label, multicenter study to evaluate the change in bone turnover markers after once monthly oral ibandronate therapy in treatment naïve postmenopausal osteoporosis patients.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 10/20/2006
Phase: II
Randomized, double-blind, placebo-controlled, multicentre, dose-ranging study to determine the tolerability and effect on bone turnover of several monthly doses of ibandronate in postmenopausal osteopenic and osteoporotic women.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 1/5/2007
Phase: IV
PRIOR Study--And open label, multi-center study to determine level of adherence to monthly oral or every three month intravenous ibandronate treatment in postmenopausal women with osteoporosis or osteopenia, who are GI intolerant of daily and/or weekly alendronate or risedronate.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 5/1/2007
Phase: III
A randomized, double-blind, double-dummy, parallel-group, multicenter study to compare the efficacy and safety of once monthly oral administration of 150mg ibandronate with once weekly oral administration of 70mg alendronate in postmenopausal osteoporosis - a non-inferiority tral.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 6/1/2007
Phase: III
Open-label, multicenter study to assess the persistance on treatment in women with postmenopausal osteoporosis receiving once-monthly ibandronic acid with either a patient support programme (PSP) or bone turnover marker monitoring (BM).
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: III
BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: To be Published
Phase: IV
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
Product Name: Bonviva/Boniva [ibandronate]
Date of Report: 10/26/2007
Phase: IV
A randomized, double-blind, placebo-controlled study to determine time to onset of suppression of the bone resorption marker sCTX with once-monthly ibandronate in the treatment of postmenopausal osteoporosis.
